Support teaching, research, and patient care.
Dr. Roham Zamanian specializes in the treatment of pulmonary hypertension, right heart failure, and pulmonary embolism. He has more than 13 years of sub-specialty experience in pulmonary vascular diseases. Dr. Zamanian is considered one of the leading national experts in clinical trials and drug development for pulmonary hypertension.
Pulmonary Hypertension Patients
Pulmonary Hypertension Association
1. Development and evaluation of prognostic and diagnostic integral biomarkers in PAH.2. Prevalence and Treatment of Insulin Resistance in PAH.3. Role of inflammation and proteomic signature in PAH4. Development of novel therapeutics (bench to bedside) including FK506 & Elastase Inhibition in PAH.5. Assessment of Vasoreactivity (gain and loss) in pulmonary arterial hypertension6. Assessment of microvascular function in PAH.
Pulmonary Hypertension Association Registry
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial
hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects
information from people with PAH and CTEPH who are cared for in participating PHA-accredited
Pulmonary Hypertension Care Centers throughout the U.S.
PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and
will observe how well these participants do. The goal is to see if people with PH are treated
according to recommended guidelines, and to see if there are certain factors that can lead to
better or worse outcomes.
PHAR will include information about people with PAH and CTEPH in the U.S. who are seen at
participating PHA-accredited PH Care Centers. PHAR contains data about patient care and
outcomes. Specifically, data in the PHAR includes information on diagnosis; clinical status;
socioeconomic status; diagnosis test results; body size; treatment information; interest in
participating in clinical trials; family health and social history; and information about
smoking, alcohol, or drug use. Participants are followed over time, and provide updates such
as changes in therapy, how often participants need to go to the hospital, and survival. Such
information may help healthcare providers provide better care.
View full details
OPsumit USers Registry
Prospective observational drug registry developed to characterize the safety profile
(including primarily potential serious hepatic risks) and to describe clinical
characteristics and outcomes of patients newly treated with Opsumit in the post-marketing
U.S. CTEPH Registry
The U.S. CTEPH Registry is a multicenter, observational, U.S.-based study of the clinical
course and treatment of patients diagnosed with chronic thromboembolic pulmonary hypertension
(CTEPH), WHO Group IV Classification for Pulmonary Hypertension. The mission of the Registry
will be to promote a greater understanding of the prevalence, pathophysiology, evaluation,
and treatment of patients with CTEPH through shared information, education, and collaborative
investigation among pulmonary hypertension (PH) centers of excellence throughout the U.S.
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) is a serious,
life-threatening manifestation of systemic sclerosis (SSc), an autoimmune disease of the
connective tissue characterized by scarring (fibrosis) and atrophy of the skin, joints and
tendons, skeletal muscles, and internal organs, and immunological disturbances. One-year
survival for patients with SSc-PAH ranges from 50-81%. There is currently no cure for SSc-PAH
and treatment is limited to vasodilator therapy used in all forms of PAH. In recent studies,
immunotherapy was shown to be effective in treating SSc-interstitial lung disease, another
serious, life-threatening manifestation of SSc. In addition, there are compelling
pre-clinical data and anecdotal clinical reports that suggest modulation of the immune system
may be an effective strategy for treating SSc-PAH. To test this approach, this trial will
determine if rituximab, an immunotherapy, has a marked beneficial effect on clinical disease
progression, with minimal toxicity, in patients with SSc-PAH when compared to placebo.
Stanford is currently not accepting patients for this trial.
For more information, please contact Val Scott, 650-725-8082.